speb/financial-data huggingface dataset:
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Cash Dividends Paid: -14822000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 11128000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -140103000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: 18242000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 14477000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Payable: 205936000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -89359000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: 16609000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Changes In Cash: 892000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Common Stock: 148224000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 586268000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Common Stock Issuance: 9128000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 55449000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 1678183000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Assets: 1845703000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 7619000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Debt: 766273000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 773892000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 1656447000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 7279000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Depreciation: 75717000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 90401000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 90401000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 75717000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 14822000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Diluted EPS: 3.79
BALPHARMA.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 56115000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 1736000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — EBIT: 180575000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — EBITDA: 270976000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Effect Of Exchange Rate Changes: 0.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — End Cash Position: 11126000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: -172215000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 199144000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Free Cash Flow: 183262000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: -12336000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 27054000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Goodwill: 38286000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 118198000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 762257000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Gross PPE: 958034000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Gross Profit: 1118806000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Interest Expense: 88752000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 88752000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Interest Income: 3701000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 3701000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Interest Paid Cff: -104036000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Interest Received Cfi: 1787000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Inventory: 743956000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Invested Capital: 1622676000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: -94848000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 18090000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 9128000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Issuance Of Debt: 30813000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 79103000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 22537000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 270135000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 292672000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Long Term Debt Issuance: 30813000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Long Term Provisions: 46941000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 558052000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Minority Interest: -1344000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Minority Interests: -934000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Business Purchase And Sale: 0.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: 9128000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Net Debt: 1025280000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: -6129000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income: 56115000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 56115000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 57048000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 56115000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 56115000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 91825000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 57048000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Interest Income: -105387000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: -11942000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -62486000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: 30813000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -105387000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Other Financing Charges: 1000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Net PPE: 611179000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -84693000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: -93299000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 468070000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 18302000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Assets: 0.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 6044000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 46941000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 10762000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 248548000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Normalized Income: 40155235.20
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: 267955000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Operating Income: 150597000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Operating Revenue: 2796989000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 15572372.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Current Assets: 3101000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Current Liabilities: 34878000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Equity Interest: 18503000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 79912000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 48808000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: 77158000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Non Current Assets: -1000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: -3000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 17338000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 230550000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Payable: 48828000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Properties: 555730000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 75652000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 49717000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Other Special Charges: -22428000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Payables: 750129000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 7279000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 195327000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Pretax Income: 91823000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Provisionand Write Offof Assets: 1588000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Purchase Of Business: 0.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -84693000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 311562000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 1678183000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 90401000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 5644000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 5644000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Research And Development: 0.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 13699000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 135813000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Sale Of PPE: 0.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 148169000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 175223000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Share Issued: 15572372.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Special Income Charges: 22428000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Stock Based Compensation: 0.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 586268000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 468070000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: 6468235.20
BALPHARMA.NS income_statement (annual, 2022-03-31) — Tax Provision: 34775000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.29
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 992000.00
BALPHARMA.NS cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -12018000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Assets: 2605327000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 856403000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Debt: 1066564000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 584924000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Total Expenses: 2646392000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 2020403000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 759624000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 363956000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 20336000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 43926000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 22428000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 22428000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Work In Process: 184442000.00
BALPHARMA.NS balance_sheet (annual, 2022-03-31) — Working Capital: 189256000.00
BALPHARMA.NS income_statement (annual, 2022-03-31) — Write Off: 0.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1079184000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — +Total Revenue: 3017073000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 789229000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 939759000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -391635000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 301839000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -14620000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Amortization: 19677000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 19677000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 13978000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 15690000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Basic EPS: 1.67
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 11127000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 251423000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -146454000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 20799000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 156899000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 14871000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 74627000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -15572000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 6192000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 8679000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Inventory: -236094000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: -21826000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 106525000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Payable: 271733000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -398421000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -275250000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Changes In Cash: 3743000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Common Stock: 156899000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 637891000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 39171000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 20199000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 1762439000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Assets: 2281559000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 8549000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1004762000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1013311000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 2093344000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 6396000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Depreciation: 71606000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 91283000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 91282000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 71605000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 15690000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Diluted EPS: 1.67
BALPHARMA.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 25717000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 1493000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — EBIT: 152445000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — EBITDA: 243728000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: 0.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — End Cash Position: 14871000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 240938000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 287451000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -161825000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -299000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 34236000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Goodwill: 38286000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 142856000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 954379000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 1033627000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Gross Profit: 1254634000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Interest Expense: 104960000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 104960000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Interest Income: 2313000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 2313000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -136834000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 1401000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Inventory: 980050000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 1947884000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -221824000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 13978000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 39171000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 117021000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 148928000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 12250000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 305231000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 317481000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 117021000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 50675000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 613077000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Minority Interest: -869000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Minority Interests: -475000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Business Purchase And Sale: 0.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 39171000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Debt: 1295122000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: 8194000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income: 25717000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 25717000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 26193000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 25717000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 25717000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 47485000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 26193000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Interest Income: -120825000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -8101000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 354173000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 117021000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -120825000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 4798000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -1000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Net PPE: 641992000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -146454000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 237152000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 495035000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 4511000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 21666000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 28691000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 50675000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 25430000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 242399000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Normalized Income: 24703770.40
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: -15371000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Operating Income: 175450000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Operating Revenue: 3017073000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 15689872.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 2532000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 53770000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 13926000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 104570000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 53634000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 116269000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 2422000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: -1000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 5764000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 265895000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 9975000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 621792000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 37260000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 59756000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Other Special Charges: -1329000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Payables: 860752000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 6396000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 233169000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Pretax Income: 47485000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 1820000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of Business: 0.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -146454000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 364116000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 1762439000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 91283000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 7636000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 7636000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Research And Development: 0.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 14162000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 146886000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 147741000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 181977000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 15689872.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Special Income Charges: 1329000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Stock Based Compensation: 0.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 637891000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 495035000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 315770.40
BALPHARMA.NS income_statement (annual, 2023-03-31) — Tax Provision: 21292000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.24
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 1453000.00
BALPHARMA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -5044000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 3131723000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 943122000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 1330792000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 637022000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Total Expenses: 2841623000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 2494701000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 850164000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 401357000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 18178000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 60055000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 1329000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 1329000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Work In Process: 274849000.00
BALPHARMA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 188215000.00
BALPHARMA.NS income_statement (annual, 2023-03-31) — Write Off: 0.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1093841000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 3392196000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 774643000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 996218000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -458663000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 312875000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -16550000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Amortization: 39204000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 39204000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 2809000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 15738000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Basic EPS: 4.96
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 14871000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 281105000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -109800000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 26514000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 158044000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 41957000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 199290000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -15690000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 9245000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 32712000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 101936000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 10390000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -7201000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Payable: -5951000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -142932000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -40428000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 27086000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 158044000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 720044000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 5012000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 26493000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 1951860000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Assets: 2341616000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 12772000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1032496000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1045268000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 2030572000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 9487000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation: 61507000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 100711000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 100711000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 61507000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 15738000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Diluted EPS: 4.96
BALPHARMA.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 73922000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 1199000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — EBIT: 219519000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — EBITDA: 336008000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Effect Of Exchange Rate Changes: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — End Cash Position: 41958000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -12063000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 263785000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 118258000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -826000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 46274000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill: 38269000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 152082000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 1012768000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 1128260000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Gross Profit: 1311590000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense: 144823000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 144823000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income: 5596000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 5596000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -163263000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 6886000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Inventory: 878115000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 2116034000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -188909000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 2809000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 5012000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 58263000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 148928000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 13742000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 363494000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 377236000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 58263000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 50860000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 671734000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Minority Interest: -329000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Minority Interests: -535000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 5012000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Debt: 1354033000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -10353000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income: 73922000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 73922000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 74458000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 73922000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 73922000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 90473000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 74457000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Interest Income: -141058000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -86114000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 161876000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 58263000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -141058000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: 2000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Net PPE: 669597000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -109681000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 103613000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 567962000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 4511000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 0.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 15489000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 50860000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 27669000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 336008000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Normalized Income: 73241399.83
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 228058000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Operating Income: 217749000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Operating Revenue: 3263450000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 15804372.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 3303000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 47744000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 6655000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 113813000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 55638000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 140266000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 1776000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: -1000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 22060000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 285642000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Payable: 10724000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Properties: 616051000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 46737000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 157333000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Other Special Charges: -827000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Payables: 808742000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 9487000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 208486000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Pretax Income: 90473000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 1930000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -109800000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 249527000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 1951860000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 100711000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 10492000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 10492000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 9467000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 220521000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 119000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 174465000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 220739000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Share Issued: 15804372.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Special Income Charges: 0.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 0.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 720044000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 567962000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 146399.83
BALPHARMA.NS income_statement (annual, 2024-03-31) — Tax Provision: 16016000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.18
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 1167000.00
BALPHARMA.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -45432000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Assets: 3198383000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 1083538000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Debt: 1422504000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 719715000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Total Expenses: 3045701000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 2478668000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 856767000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 448096000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 17608000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 22176000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 827000.00
BALPHARMA.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 827000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Work In Process: 309165000.00
BALPHARMA.NS balance_sheet (annual, 2024-03-31) — Working Capital: 311044000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 783181000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 1031974000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 23837000.00
BALPHARMA.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 16029231.00
BALPHARMA.NS income_statement (quarterly, 2024-09-30) — Basic EPS: 0.65
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 19497000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 261558000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 159209000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 687918000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 17077000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 2482068000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 1160143000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1160143000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 2207085000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 9527000.00
BALPHARMA.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 16029231.00
BALPHARMA.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: 0.65
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 38286000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 153605000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 656526000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 898686000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 2237445000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 23837000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 389384000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 389384000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 54160000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: -336000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 1530030000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 656526000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 534313000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 24121000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 36224000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 15920872.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 264893000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 74685000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 528709000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 115319000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 53413000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 639449000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 23245000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 242061000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Payables: 802925000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 15920872.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 687918000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 534313000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 1712000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 3395064000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 1077302000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 1549527000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 687582000.00
BALPHARMA.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 2707482000.00